Status:
COMPLETED
Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)
Lead Sponsor:
Applied Spectral Imaging Ltd.
Conditions:
Bladder Cancers
Eligibility:
All Genders
Brief Summary
The purpose of the study is the identification of chromosomal aberrations in urine samples. The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting a...
Detailed Description
The FISH test detect chromosomal aberrations in urine specimens from persons with hematuria suspected of having bladder cancerous using the UroVysion® Bladder Cancer Kit (UroVysion Kit) which is FDA a...
Eligibility Criteria
Inclusion
- Well stained slides with bright FISH signals
Exclusion
- Very old slides that were already bleached
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT01264744
Start Date
November 1 2009
End Date
August 1 2010
Last Update
December 23 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Hospital
Los Angeles, California, United States, 90073
2
PLUS Diagnostics
Union, New Jersey, United States, 07083
3
Sheila Dobin, Ph.D.
Temple, Texas, United States, 76508